Personalis Inc (PSNL)

$8.14 -0.27 (-3.21%)
Market Cap 746.84M
Revenue (ttm) 84.61M
Net Income (ttm) -81.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -96.06%
Debt to Equity Ratio 0.00
Volume 454,700
Avg Vol 1,634,148
Day's Range N/A - N/A
Shares Out 88.80M
Stochastic %K 43%
Beta 1.99
Analysts Strong Sell
Price Target $11.00

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 752 1300
Fax: 650 752 1301
Address:
6600 Dumbarton Circle, Fremont, United States
magnitudeFC
magnitudeFC Dec. 26 at 4:20 PM
$PSNL Any precedent to MolDX giving reimbursement decisions the last week of the year or all of them on holiday now? I know I'm clutching at straws and a month or two doesn't matter in the grand scheme of things but boy would it be nice to get that second reimbursement to close out 2025
1 · Reply
BioTechNoir
BioTechNoir Dec. 26 at 3:18 PM
$PSNL bought $100 we’re turning this around 🤣🤣
1 · Reply
Ir1ne_Craig
Ir1ne_Craig Dec. 26 at 2:00 PM
$PSNL biotech microcap low float asymmetry if volume shows
0 · Reply
ExNoose
ExNoose Dec. 26 at 1:10 PM
$PSNL Shorts not ready to throw in the towel yet. 2026 will be a year to remember for shorts and for longs 🙄
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 12:55 PM
🔎 $PSNL Options Scan Update (06:55 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
arribaStocktrading
arribaStocktrading Dec. 26 at 12:27 PM
$PSNL Only 3 and 1/2 trading days remain for this year... the Median return for all stocks is negative - minus 1 percent YTD... it's actually lower than that because stocks that went full bust or were delisted have been removed from this gauge. It could have been much worse however and it remains to be seen if the cracks in the economy get bigger or not. Most of the market forecasters see double-digit returns in the coming year for the market but that is an aggregate number driven by a select few stocks that have tremendously oversized influence. The US economy is just UGH to me right now. It's extremely top heavy in an unhealthy sort of way... Top 10 percent (wealthiest ) now account for 50 percent of all spending and AI Data Centers are becoming fierce competitors for land, water and resources.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 26 at 3:13 AM
Enter: $PSNL Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.10 - $0.35 Sell Price: $0.15 Profit : +51% (Turn every $1 into $1.51) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Penki1985
Penki1985 Dec. 25 at 5:44 PM
$PSNL Looks like a bullish divergence. Up from here.
0 · Reply
1iquid
1iquid Dec. 25 at 2:19 PM
💎 Liquid® Live Actionable Trade Asset: $PSNL Contracts: $PSNL July 17, 2026 $10 Calls Scale in: $2.55- $3.11 Scale out: $9.91-$16.98 Profit Potential : 376% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 5:32 PM
Enter: $PSNL Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.52 - $0.55 Sell Price: $0.94 Profit : +80% (Turn every $1 into $1.80) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Latest News on PSNL
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

Dec 17, 2025, 6:00 AM EST - 9 days ago

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Dec 11, 2025, 9:00 AM EST - 15 days ago

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 4:01 PM EST - 5 weeks ago

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Nov 10, 2025, 9:00 AM EST - 6 weeks ago

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 9:46 PM EST - 7 weeks ago

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Personalis Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:01 PM EST - 7 weeks ago

Personalis Reports Third Quarter 2025 Financial Results

Personalis to Announce Third Quarter 2025 Financial Results

Oct 21, 2025, 4:01 PM EDT - 2 months ago

Personalis to Announce Third Quarter 2025 Financial Results

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Oct 16, 2025, 9:00 AM EDT - 2 months ago

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 15, 2025, 5:35 PM EDT - 3 months ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 10, 2025, 4:05 PM EDT - 3 months ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Sep 3, 2025, 4:05 PM EDT - 4 months ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Personalis to Participate in Upcoming Investor Conferences

Aug 27, 2025, 4:01 PM EDT - 4 months ago

Personalis to Participate in Upcoming Investor Conferences

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Aug 6, 2025, 8:11 AM EDT - 5 months ago

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

SMCI

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 10:49 PM EDT - 5 months ago

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Personalis Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 4:01 PM EDT - 5 months ago

Personalis Reports Second Quarter 2025 Financial Results

Personalis to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 5 months ago

Personalis to Announce Second Quarter 2025 Financial Results

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

Jul 9, 2025, 4:00 PM EDT - 6 months ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 3, 2025, 4:00 PM EDT - 7 months ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

Jun 2, 2025, 4:00 PM EDT - 7 months ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 22, 2025, 6:00 AM EDT - 7 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 14, 2025, 4:01 PM EDT - 8 months ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

May 6, 2025, 8:41 PM EDT - 8 months ago

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

Personalis Reports First Quarter 2025 Financial Results

May 6, 2025, 4:01 PM EDT - 8 months ago

Personalis Reports First Quarter 2025 Financial Results

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Apr 28, 2025, 5:00 PM EDT - 8 months ago

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 4:01 PM EDT - 8 months ago

Personalis to Announce First Quarter 2025 Financial Results

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Apr 22, 2025, 6:00 AM EDT - 8 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 4:01 PM EDT - 9 months ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Mar 3, 2025, 6:00 AM EST - 10 months ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:40 PM EST - 10 months ago

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 4:01 PM EST - 10 months ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Feb 21, 2025, 4:21 PM EST - 11 months ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

ARDX GERN MRNA TEM

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Feb 18, 2025, 4:01 PM EST - 11 months ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Exciting Technology At Personalis, But Profitability Eludes Them

Feb 14, 2025, 10:50 AM EST - 11 months ago

Exciting Technology At Personalis, But Profitability Eludes Them

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 4:01 PM EST - 11 months ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 28, 2025, 4:01 PM EST - 11 months ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Jan 13, 2025, 5:00 AM EST - 1 year ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Jan 7, 2025, 4:01 PM EST - 1 year ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Dec 19, 2024, 9:00 AM EST - 1 year ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Personalis and Tempus Expand Collaboration to Biopharma

Dec 16, 2024, 8:00 AM EST - 1 year ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM

Personalis to Participate at Upcoming Investor Conferences

Nov 20, 2024, 4:01 PM EST - 1 year ago

Personalis to Participate at Upcoming Investor Conferences

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:11 PM EST - 1 year ago

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Personalis Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:01 PM EST - 1 year ago

Personalis Reports Third Quarter 2024 Financial Results

Personalis to Present at the Stifel 2024 Healthcare Conference

Nov 5, 2024, 4:01 PM EST - 1 year ago

Personalis to Present at the Stifel 2024 Healthcare Conference

Personalis to Announce Third Quarter 2024 Financial Results

Oct 23, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce Third Quarter 2024 Financial Results

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Sep 16, 2024, 9:00 AM EDT - 1 year ago

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Personalis: Resetting My Strategy Following The Q2 Beat

Aug 18, 2024, 7:47 AM EDT - 1 year ago

Personalis: Resetting My Strategy Following The Q2 Beat

Personalis and Tempus Announce Expanded Collaboration

Aug 16, 2024, 8:30 AM EDT - 1 year ago

Personalis and Tempus Announce Expanded Collaboration

TEM

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 11:09 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Personalis Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Personalis Reports Second Quarter 2024 Financial Results

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Jul 31, 2024, 4:01 PM EDT - 1 year ago

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

magnitudeFC
magnitudeFC Dec. 26 at 4:20 PM
$PSNL Any precedent to MolDX giving reimbursement decisions the last week of the year or all of them on holiday now? I know I'm clutching at straws and a month or two doesn't matter in the grand scheme of things but boy would it be nice to get that second reimbursement to close out 2025
1 · Reply
BioTechNoir
BioTechNoir Dec. 26 at 3:18 PM
$PSNL bought $100 we’re turning this around 🤣🤣
1 · Reply
Ir1ne_Craig
Ir1ne_Craig Dec. 26 at 2:00 PM
$PSNL biotech microcap low float asymmetry if volume shows
0 · Reply
ExNoose
ExNoose Dec. 26 at 1:10 PM
$PSNL Shorts not ready to throw in the towel yet. 2026 will be a year to remember for shorts and for longs 🙄
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 12:55 PM
🔎 $PSNL Options Scan Update (06:55 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
arribaStocktrading
arribaStocktrading Dec. 26 at 12:27 PM
$PSNL Only 3 and 1/2 trading days remain for this year... the Median return for all stocks is negative - minus 1 percent YTD... it's actually lower than that because stocks that went full bust or were delisted have been removed from this gauge. It could have been much worse however and it remains to be seen if the cracks in the economy get bigger or not. Most of the market forecasters see double-digit returns in the coming year for the market but that is an aggregate number driven by a select few stocks that have tremendously oversized influence. The US economy is just UGH to me right now. It's extremely top heavy in an unhealthy sort of way... Top 10 percent (wealthiest ) now account for 50 percent of all spending and AI Data Centers are becoming fierce competitors for land, water and resources.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 26 at 3:13 AM
Enter: $PSNL Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.10 - $0.35 Sell Price: $0.15 Profit : +51% (Turn every $1 into $1.51) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Penki1985
Penki1985 Dec. 25 at 5:44 PM
$PSNL Looks like a bullish divergence. Up from here.
0 · Reply
1iquid
1iquid Dec. 25 at 2:19 PM
💎 Liquid® Live Actionable Trade Asset: $PSNL Contracts: $PSNL July 17, 2026 $10 Calls Scale in: $2.55- $3.11 Scale out: $9.91-$16.98 Profit Potential : 376% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 5:32 PM
Enter: $PSNL Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.52 - $0.55 Sell Price: $0.94 Profit : +80% (Turn every $1 into $1.80) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
magnitudeFC
magnitudeFC Dec. 24 at 3:27 PM
$PSNL Kinda surprised we are selling off here. Classic short term thinking from investors. MRD is quite obviously going to be a very large market in the coming years and Personalis is in the heart of it. I think we will be rewarded over the long term. Anyways I've enjoyed interacting with you guys over the course of the year - you all know who you are! Merry Christmas and Happy Holidays!
2 · Reply
lucianw
lucianw Dec. 24 at 2:48 PM
$PSNL well we are about to wrap up another turbulent year. While I feel the SP performance has been rather underwhelming considering our developments, things should hopefully turn around once we have the other two approvals. In the near term I kinda look forward to the early January update considering we already have one approval covering 4Q25. Who knows, we might be looking at some nice surprise in terms test volume and topline. Anyway, Merry Christmas guys!
1 · Reply
OdeOrder
OdeOrder Dec. 24 at 11:57 AM
$PSNL Future price discovery depends on how progress validates the underlying thesis beyond narrative appeal. Inconsistent delivery may prolong volatility.
2 · Reply
arribaStocktrading
arribaStocktrading Dec. 23 at 3:07 PM
$PSNL I really hate the end of year because it's gamed as fuck. Stocks that had a good year have no worries... people want to keep those but stocks that had a bad year get kicked some more: their bids dropped because the Market Markers know that Tax Loss Sellers will sell to them at distressed prices. Like Strawberry Fields.... nothing is real.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 22 at 11:36 PM
Enter: $PSNL Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.45 - $0.65 Sell Price: $0.85 Profit : +89% (Turn every $1 into $1.89) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
BioTechNoir
BioTechNoir Dec. 22 at 4:01 PM
$PSNL 2026 our year
0 · Reply
arribaStocktrading
arribaStocktrading Dec. 22 at 1:20 PM
$PSNL So Trump takes a mental competency test that actually awards you points if you can tell the difference between a crayon and a piano. Miracle of Miracles he passes. Do you think he could do what we do? No fucking way. So be proud even if you don't have Qatar providing you with your own personal luxury jet. Back to double D's soon... the kind we like.... actually we like both kinds but I mean digits !
1 · Reply
RockyMontana
RockyMontana Dec. 22 at 11:04 AM
$PSNL
1 · Reply
GGator
GGator Dec. 21 at 11:22 PM
$PSNL is this the week?
1 · Reply
1iquid
1iquid Dec. 21 at 3:11 PM
💎 Liquid® Live Actionable Trade Asset: $PSNL Contracts: $PSNL July 17, 2026 $10 Calls Scale in: $2.48- $3.03 Scale out: $9.64-$16.53 Profit Potential : 300% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 20 at 10:46 PM
Enter: $PSNL Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.36 - $0.65 Sell Price: $0.54 Profit : +49% (Turn every $1 into $1.49) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
TripleWitch
TripleWitch Dec. 20 at 7:44 PM
$PSNL this 1 minute purchase was roughly equivalent to 10% of the outstanding float-massive accumulation 💥 🔥 💥
0 · Reply